Thomas Schmid, partner in the Munich Office and head of Orrick's German M&A and private equity team, advises on M&A, private equity and venture capital investments.

Thomas represents clients in national and cross-border transactions, in particular local and international corporates, private equity/venture funds and high growth companies.

He has advised transactions in all sectors but has developed particular expertise in the tech and lifescience/healthcare area.

His practice also covers also capital markets, restructuring and general corporate/commercial matters.

Thomas is consistently recognized as leading lawyer in his practice in Germany.

Prior to joining Orrick, he was, inter alia, a partner in the Munich office of an international law firm Weil, Gotshal & Manges LLP and Inhouse Counsel at MAN AG.

  • Advising Vitruvian as lead investor in the $65 Million Series D financing of Smava

    Advising Digital+ Partners on their investment in U.S. driving technology innovator Cellcontrol

    Advising Swedish private equity firm EQT on the sale of its shares in Germany’s BackWerk Group to Switzerland’s Valora Group.

    Advising Atomico in $90m Series B Financing of Lilium.

    Advising WTC (Ironman) on Acquisition of Swiss Epic AG.

    Advising diverse Startups in connection with incorporation of financing rounds in particular in the Tech, BioTech and Healthcare sector

    Advising Fonds Finanz Maklerservice GmbH acquisition of softfair Gmbh and others

    Advising DBAG on its investment in Radiology Group of Companies

    Advising the sale of iTAC Software AG to Dürr AG

    Advising Technology Crossover Ventures on its investment in

    Advising Morphosys AG on their corporate venture capital investment in Dutch start-up Lanthio Pharma

    Advising World Triathlon Corporation (Ironman) on the acquisition of Lagardère Sports‘ endurance division

    Advising the Refinancing of RLG Group with Proventus Capital Partners

    Advising Eli Lilly, inter alia, on the acquisition of the animal health division from Novartis and Lohmann SE

    Advising EQT Expansion Capital II Fund on the investment in UDG United Digital Group

    Advising BetClick Everest Group on the acquisition of

    Advising Access Industries on its investment in Rocket Internet AG and its subsidiaries

    Advising MorphoSys AG on the acquisition of Sloning and the sale of AbD Serotec to Bio-Rad Laboratories, Inc.

    Advising Monitor Clipper Partners, LLC on its acquisition of Sengelwald Klinikprodukte GmbH

    Advising Atos Origin on the acquisition of Siemens IT Solutions and Services

    Advising Saban Capital Group  and other private equity firms on the disposal of ProSiebenSat.1 Media AGText